A Phase I Multicenter Study of Continuous Oral Administration of Lonafarnib (SCH 66336) and Intravenous Gemcitabine in Patients With Advanced Cancer-Reference-Cited by-同舟云学术

A Phase I Multicenter Study of Continuous Oral Administration of Lonafarnib (SCH 66336) and Intravenous Gemcitabine in Patients With Advanced Cancer

Published:2011-10-19 Issue:9 Volume:29 Page:617-625
ISSN:0735-7907
Container-title:Cancer Investigation
language:en
Short-container-title:Cancer Investigation

Author:

Wong Nan Soon,Meadows Kellen L.,Rosen Lee S.,Adjei Alex A.,Kaufmann Scott H.,Morse Michael A.,Petros William P.,Zhu Yali,Statkevich Paul,Cutler David L.,Meyers Michael L.,Hurwitz Herbert I.

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.3109/07357907.2011.621912

Reference61 articles.

1. Regulation of the mevalonate pathway

2. Prenylation of Ras GTPase Superfamily Proteins and Their Function in Immunobiology

3. Enzymatic Coupling of Cholesterol Intermediates to a Mating Pheromone Precursor and to the Ras Protein

4. Protein farnesylation: Implications for normal physiology, malignant transformation, and cancer therapy

5. p21ras is modified by a farnesyl isoprenoid.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges;International Journal of Molecular Sciences;2022-08-20

2. The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures;Frontiers in Oncology;2021-12-23

3. Targeting KRAS in NSCLC: Old Failures and New Options for “Non-G12c” Patients;Cancers;2021-12-16

4. HBV and HDV: New Treatments on the Horizon;Journal of Clinical Medicine;2021-09-08

5. RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients;European Journal of Cancer;2021-03